Get notified of page updates

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

Recurrent ovarian cancer

Clinicaltrials.gov identifier:
NCT03462342
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

About the Study

This study is no longer recruiting patients. 

This study will look at how well patients with recurrent ovarian, primary peritoneal or cancer respond to treatment with a known as an ATR inhibitor when combined with the Olaparib.

 

This Study is Open To:

This study is no longer recruiting patients. 

This Study is NOT Open To:

This study is no longer recruiting patients. 

Recurrent ovarian cancer

Clinicaltrials.gov identifier:
NCT03462342
PRINTER FRIENDLY PAGE